Player FM 앱으로 오프라인으로 전환하세요!
January 2024 Neurology Recall: Topics in Dementia
Manage episode 510143240 series 9882
The January 2024 replay starts the new year off with four previously posted episodes on dementia. The episode begins with an interview with Dr. Kenneth Langa on the prevalence of dementia and mild cognitive impairment in the US. The episode continues with an interview with Dr. Beau Ances about the burden amyloid has on individuals with Down syndrome compared to autosomal dominant Alzheimer disease. The next interview is with Dr. Erik Musiek on the use of lecanemab in early Alzheimer disease. The fourth and final interview is with Dr. Vijay Ramanan on the eligibility for anti-amyloid treatment.
Related Podcast Links:
Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the United States: https://directory.libsyn.com/episode/index/id/25811241
Comparison of Amyloid Burden in Individuals with Down Syndrome Versus Autosomal Dominant Alzheimer Disease: https://directory.libsyn.com/episode/index/id/25881414
Lecanemab in Early Alzheimer Disease: https://directory.libsyn.com/episode/index/id/25428333
Eligibility for Anti-Amyloid Treatment: https://directory.libsyn.com/episode/index/id/28300052
Related Article Links:
Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the US: https://jamanetwork.com/journals/jamaneurology/article-abstract/2797274?resultClick=1
Comparison of Amyloid Burden in Individuals with Down Syndrome Versus Autosomal Dominant Alzheimer's Disease: A Cross-Sectional Study: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00408-2/fulltext
Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging: https://www.neurology.org/doi/10.1212/WNL.0000000000207770
Disclosures can be found at Neurology.org
1076 에피소드
Manage episode 510143240 series 9882
The January 2024 replay starts the new year off with four previously posted episodes on dementia. The episode begins with an interview with Dr. Kenneth Langa on the prevalence of dementia and mild cognitive impairment in the US. The episode continues with an interview with Dr. Beau Ances about the burden amyloid has on individuals with Down syndrome compared to autosomal dominant Alzheimer disease. The next interview is with Dr. Erik Musiek on the use of lecanemab in early Alzheimer disease. The fourth and final interview is with Dr. Vijay Ramanan on the eligibility for anti-amyloid treatment.
Related Podcast Links:
Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the United States: https://directory.libsyn.com/episode/index/id/25811241
Comparison of Amyloid Burden in Individuals with Down Syndrome Versus Autosomal Dominant Alzheimer Disease: https://directory.libsyn.com/episode/index/id/25881414
Lecanemab in Early Alzheimer Disease: https://directory.libsyn.com/episode/index/id/25428333
Eligibility for Anti-Amyloid Treatment: https://directory.libsyn.com/episode/index/id/28300052
Related Article Links:
Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the US: https://jamanetwork.com/journals/jamaneurology/article-abstract/2797274?resultClick=1
Comparison of Amyloid Burden in Individuals with Down Syndrome Versus Autosomal Dominant Alzheimer's Disease: A Cross-Sectional Study: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00408-2/fulltext
Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging: https://www.neurology.org/doi/10.1212/WNL.0000000000207770
Disclosures can be found at Neurology.org
1076 에피소드
모든 에피소드
×플레이어 FM에 오신것을 환영합니다!
플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.